Combine Able AI Ltd

Based in Israel, Combine Able AI Ltd specializes in AI-driven solutions for the rapid design and optimization of biologics, including complex multispecific formats, enhancing therapeutic development timelines. Combine Able AI Ltd, founded in 2023 and headquartered in Rehovot, Israel, focuses on AI-driven biologics design. The firm has completed one deal as of January 12, 2026. The founder's history is not specified, and there are no mentions of subsidiaries or significant pivots in business strategy.

CombinAble focuses on developing an AI-driven platform designed for the rapid in silico design and optimization of next-generation biologics, including classic antibodies and complex multispecific formats such as bi-specifics, tri-specifics, and T-cell engagers. This platform significantly accelerates therapeutic design timelines, achieving optimized antibody development in a mere four months, compared to traditional methods that can take 12 to 18 months. The company’s technology addresses challenges associated with therapeutic design, particularly the complexities of multispecific antibodies, by employing advanced computational models that enhance binding affinity, specificity, and stability. CombinAble serves a diverse client base that includes leading pharmaceutical and technology companies, primarily within North America and Europe, facilitating the development of biologics targeting a wide array of diseases.

CombinAble generates revenue through partnerships and collaborations with pharmaceutical and biotechnology companies that seek advanced solutions for biologics development. The company’s business model typically involves B2B transactions, where clients engage the platform to optimize their products, often through milestone-based agreements that align with project completion timelines. The pricing structure for their services varies based on the complexity and scope of the client’s needs, reflecting the bespoke nature of the solutions provided. Clients benefit from access to CombinAble's proprietary AI technology, enabling the development of best-in-class therapeutics, including flagship products focused on improving specific therapeutic outcomes.

The company is well-positioned to capitalize on the growing demand for innovative biologics, with its services integral to the research and development efforts of major industry players. In January 2026, Insitro, Inc. , a portfolio company of various prominent investors, agreed to acquire CombinAble AI. This acquisition will enable the integration of company’s biologics design capabilities, unifying therapeutic design across modalities through the TherML platform, and improving development processes from target discovery to assessment.

Future growth initiatives include expanding into new markets and regions to enhance their service offerings and meet the increasing demand for biologics solutions.